


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

SIHUAN PHARMACEUTICAL'S SUBSIDIARY JILIN

HUIHENG BIOPHARMACEUTICAL CO., LTD.

COMPLETED ROUND A+ FINANCING SUCCESSFULLY

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group’s non-wholly owned subsidiary, Jilin Huisheng Biopharmaceutical Co., Ltd. (“**Huisheng Biopharmaceutical**”), has successfully completed the round A+ financing by way of capital increase (the “**Capital Increase**”) from Series A+ investors consisting of Jilin Baixing Bairong Investment Center (Limited Partnership)* (吉林百興百榮投資中心(有限合夥)) (“**Baixing Bairong**”), JiLin Province Private Equity Co., Ltd. (“**JLPE**”), Jilin Province Technology Investment Fund Co., Ltd. (“**JLTI**”) and Wuxi Shangwei Venture Capital Partnership (L.P.)* (無錫尚惟創業投資合夥企業(有限合夥)) (“**Wuxi Shangwei**”) (collectively, the “**Series A+ Investors**”).

Pursuant to the Capital Increase agreement, the Series A+ Investors subscribed for the additional registered capital of RMB38,666,667 of Huisheng Biopharmaceutical at a consideration of RMB580 million (equivalent to approximately HK\$650 million). After the completion of the Capital Increase, the registered capital of Huisheng Biopharmaceutical increased to RMB372 million, and the overall post-investment valuation was RMB5.58 billion, of which the Group’s shareholding in Huisheng Biopharmaceutical is approximately 61.29% and the Series A+ Investors’ shareholding in Huisheng Biopharmaceutical is 10.4% in total.

About the Series A+ Investors

Baixing Bairong is the lead investor in the Capital Increase, and JLPE, JLTl and Wuxi Shangwei are the co-investors. Among them, the lead investor, Baixing Bairong, is a special investment fund jointly set up by Shanghai Angell Asset Management Co., Ltd., together with several investors including JLPE and Changchun Equity Investment Fund Management Co., Ltd.* (長春市股權投資基金管理有限公司), to provide key support to high-quality enterprises in Jilin Province.

About Huisheng Biopharmaceutical

Huisheng Biopharmaceutical is a biopharmaceutical company under Sihuan Pharmaceutical, a large domestic pharmaceutical and medical aesthetics group, focusing on the areas of diabetes and complications. After 7 years of construction and development, the company currently has a world-class R&D team of more than 200 people with rich experience in diabetes drug research and development. At present, it has more than 40 products in the whole product pipeline of diabetes and complications, covering a full range of second-, third-, and fourth-generation insulin and analog product pipelines (covering basic, premixed and quick-acting products), innovative drugs with the latest mechanism, such as SGLT-2, GLP-1, and other hypoglycemic drugs and complication drugs of various mechanisms. Huisheng Biopharmaceutical is currently the only biopharmaceutical company in China that has achieved full product coverage in the field of diabetes and related complications, and integrated the whole industrial chain of R&D, production and sales. It is committed to providing full-process, all-round integrated treatment solutions for diabetic patients, serving patients and making health easier.

The proceeds from the Capital Increase are mainly used for purposes including without limitation marketing of the products launched by Huisheng Biopharmaceutical and its subsidiaries, advancing clinical trials of products under development and replenishment of operating liquidity. The successful completion of the Capital Increase of Huisheng Biopharmaceutical reflects the investors' recognition of the R&D capabilities and industrialization capacity of Huisheng Biopharmaceutical, and their confidence and expectation in the value creation of the company's full product pipeline in the field of diabetes and complications, as well as its broad market prospect in the future.

Listing Rules Implications

As at the date of this announcement, to the best knowledge, information and belief of the Directors after making all reasonable enquiries, the Series A+ Investors are third parties independent from the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). Therefore, according to Chapter 14A of the Listing Rules, the Capital Increase does not constitute a connected transaction. Besides, as the highest applicable percentage ratios in respect of the Capital Increase according to Rule 14.07 of the Listing Rules is less than 5%, the Capital Increase does not constitute a discloseable transaction under Chapter 14 of the Listing Rules.

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and biopharmaceutical company led and driven by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic objective of “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavours to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 3 January 2023

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.

* *For identification purpose only*